Credits: IMDb
“I'm not great at the advice. Can I interest you in a sarcastic comment?”

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.
Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.
Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.
However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.
Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”
In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.
There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.
Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.
Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.
If it was not his session, then how did he get ketamine?
Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.
Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.
Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.
Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”
Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.
Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.
He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.
Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”
The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”
The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”
Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.
Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.
He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.
Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”
Five arrests have been made in the case so far.
Credit: iStock/LinkedIn
Policymakers attending the 31st Conference of the Parties (COP31) in Türkiye must put health at the centre of every climate negotiation, Professor Marina Romanello, Executive Director of the Lancet Countdown, told HealthandMe in an exclusive interview.
Marina, who led the 2026 Lancet Countdown on Health and Climate Change report released ahead of COP31, outlined the growing health consequences of global warming and the urgent need for stronger climate action.
Drawing on findings from the report, Marina warned that climate inaction is putting lives, livelihoods and public health at risk.
The report noted that climate commitments made since the Paris Agreement have delivered measurable health benefits, but progress remains too slow and uneven.
“One of the things that we are calling for negotiators to realise is that when they go to COP, they're not just negotiating budgets or carbon emissions or degrees of heating. What they're negotiating is people's health,” Marina told HealthandMe.
“They're negotiating how many people die from climate change. They're negotiating how many of our children will grow in these dangerous environments and have less of a chance in life.”
She stressed the need to recognise that climate change is not just an environmental issue.
“It's important to be very clear that climate change is not just a problem of the inanimate world or even of nature and polar bears. It's a problem of people here and today, and that our failure to act is costing people's lives, livelihood and health.”
Also read: Climate Change Is Already Harming Health: WHO Chief Pushes Antalya Initiative At COP31
Marina, who is also a researcher at University College London's Institute for Global Health, urged policymakers to integrate health into all COP31 discussions rather than confining it to side events.
“We're also calling for countries not just to have climate change as one of the action agenda items and side events, but to actually consider climate change throughout their whole negotiations. Every negotiation stream needs to have health considerations so that we are aware of the hazards and the dangers that we're dealing with here.”
Read More: COP31 Begins On Health Day: How Will Countries Measure The Health Impact Of Climate Change?
Marina described COP as “a baseline” and “a starting point”, stressing that countries could go much further than the commitments agreed at the conference.
She cited India as an example of a country that stands to gain significantly from accelerating its climate transition, pointing to its natural resources, technological capabilities and opportunities to improve public health.
“In a country like India, where you have so many natural resources, where you have such impressive technology development, where you have so many opportunities from healthier air, improving access to energy, improving the transition towards more resilient, sustainable food systems, you are standing to win so massively from an accelerated transition at a country level.”
Marina also pointed out that countries rarely account for the health implications of their mitigation and adaptation plans. These include both potential negative impacts and the significant health benefits that stronger climate action could deliver.
Taking these benefits into account, she told HealthandMe, that it could increase the overall return on investment and make climate action more cost-effective.
READ: Climate Crisis Is A Health Crisis: Just 6 Actions Could Save 1.6 Million Lives, Says WHO
Marina outlined three key areas for government action at COP31:
1. Phase Out Fossil Fuels
Governments must prioritise phasing out fossil fuel use, particularly in urban centres where people live, she said.
“That will reduce the burden of air pollution and will mean that people have much less burden of chronic conditions and much less exacerbation of those conditions that they already have.”
2. Strengthen Healthcare Systems
Marina called for health systems to be equipped to respond to climate hazards and for healthcare professionals to receive training on climate change and health.
“They should know how to recommend better care and better preventative measures to their patients.”
3. Accelerate Emissions Reductions
Marina stressed that reducing greenhouse gas emissions must remain a priority for every country.
“We absolutely need to stop our emissions, our greenhouse gas emissions. Every country needs to pursue efforts to reduce their greenhouse gas emissions. It's a global health imperative.”
She added: “Reducing our greenhouse gas emissions in line with the Paris Agreement, redoubling efforts to mitigate climate change is a health imperative.”
Credit: iStock
Ozempic and Wegovy, whose active ingredient is semaglutide, have transformed the treatment of type 2 diabetes and obesity. These medications have also been linked to improved fertility in some cases. However, GLP-1 medications are not recommended during pregnancy.
Now, a study in pregnant sheep has found that semaglutide significantly reduced blood flow to the uterus and oxygen levels in developing fetuses.
Led by researchers at Adelaide University, the animal study raises questions about the potential effects of these medications on fetal development.
While the findings are preliminary and have not been established in humans, they highlight the need to understand the risks of exposure during pregnancy, particularly among women who may conceive unexpectedly or continue treatment before realising they are pregnant.
Also read: Woman Says GLP-1 Drug Helped Her Conceive
Adelaide University researcher Dr Mitchell Lock noted that although weight-loss medications have become incredibly popular, there's still a lot we don't know about how they might affect a developing baby.
With the new study, they aimed to better understand the potential effects of GLP-1 drugs during pregnancy so women and health care professionals can make informed and safe decisions about their use.
In the study, the researchers used magnetic resonance imaging (MRI) to assess maternal heart function and uterine blood flow before and after administering semaglutide to pregnant sheep. They also collected fetal blood samples and monitored blood pressure and heart rate to evaluate the drug's immediate effects.
The findings, published as a conference abstract in the journal Heart, Lung and Circulation, showed that semaglutide affected the mother's cardiovascular system and the supply of blood and oxygen to the developing fetus.
"Within two hours of administering semaglutide, we found that the amount of blood pumped by the mother's heart had significantly decreased, reducing blood flow to the uterus and lowering oxygen levels in the developing fetus," Lock said.
"Oxygen is essential for healthy fetal growth and development, so any reduction in its supply raises questions about what might happen if exposure to the drug continues throughout pregnancy."
Read More: GLP-1 Drugs Ozempic, Zepbound Use Rises 24-Fold Among American Women After Childbirth
Senior researcher Janna Morrison said the findings highlight the need for further research into the potential effects of prolonged semaglutide exposure during pregnancy.
"Our findings suggest a potential risk to fetal development, but we haven't yet established whether these short-term changes affect fetal growth, what happens over a longer period of semaglutide use or whether similar effects could occur in human pregnancies," Morrison said.
READ: GLP-1 Weight-Loss Drugs May Improve Fertility In Men With Obesity, Study Suggests
GLP-1 medications are not recommended for weight loss during pregnancy. Women planning to conceive should consult their healthcare professionals about discontinuing treatment.
For semaglutide, prescribing guidance recommends stopping the medication at least two months before a planned pregnancy.
Women who become pregnant while taking the medication should seek medical advice. Those who are breastfeeding should also discuss its use with their healthcare professional.
The American College of Obstetricians and Gynecologists advises against weight-loss medications during pregnancy. Women considering GLP-1 treatment should discuss its risks, benefits and timing with their healthcare professionals, particularly if they are planning to conceive.
Credit: iStock
Flu cases are rising earlier than usual in the US, with influenza A H1N1 driving most infections. A new mutation, G155E, may be contributing to the surge.
The 2026-2027 flu season began earlier than usual, with infections increasing as early as August. As of November 5, flu activity was growing or likely growing in 42 states, according to the US Centers for Disease Control and Prevention (CDC).
At least 1.7 million illnesses, 25,000 hospitalisations and 1,400 deaths have been reported so far this season.
“Early-season influenza activity is currently higher than typically observed at this time of year,” the CDC said in its FluView report for the week ending October 31.
Also read: G155E H1N1 Mutation In US Raises Concerns: Can This Year’s Flu Shot Still Protect You?
H1N1 is currently responsible for the vast majority of flu cases, marking a shift from last winter, when influenza A H3N2 subclade K, also known as the “superflu”, dominated.
The circulating H1N1 strain has acquired a new mutation called G155E. Early laboratory findings suggest it may make some strains harder for existing antibodies to recognise, potentially helping the virus evade immunity from previous infections or vaccination.
“It is different from last year’s H1N1 virus, and that mutation position (G155E) we know is important for generating protective antibody responses,” Andrew Pekosz, PhD, a virologist at the Johns Hopkins Bloomberg School of Public Health, told TODAY.com.
However, it is not yet clear whether the mutation is contributing to the early surge or making infections more severe.
“How that (mutation) is going to affect the disease spread and severity is not clear,” Pekosz said.
READ: Flu Activity Rises Early In US, UK And Japan: Why Experts Urge Vaccination Before Winter
The impact of G155E on vaccine effectiveness remains uncertain. The CDC said it was too early to determine whether the mutation would affect protection this season.
The 2026-2027 flu vaccines target three viruses: influenza A H1N1 (pdm09), influenza A H3N2 and influenza B.
Even if the circulating H1N1 strain differs from the vaccine strain, vaccination can still protect against severe illness and other circulating flu viruses.
“Even if there’s a mismatched strain, there’s two other strains that the vaccine will provide better protection against,” Pekosz said.
The American Medical Association recommends annual flu vaccination for everyone aged six months and older, unless medically contraindicated.
Read More: Flu 2026: Symptoms To Watch For As New Season Begins
Common symptoms include:
Flu symptoms can overlap with those of COVID-19, making testing important.
Antiviral medications can help reduce the severity and duration of influenza, particularly among people at higher risk of complications, including adults over 65, children under five, and immunocompromised individuals.
“You have to get that prescription fast ... within the first 48 hours after symptom onset, (or else) they don’t work as well,” Pekosz said.
Experts say the emergence of G155E is not a reason to panic but reinforces the importance of flu vaccination.
“View (this) as a sign to go out and get the flu vaccine,” Pekosz said.
It takes approximately two weeks for vaccine-induced protection to develop. Annual vaccination remains an important way to reduce the risk of severe flu, complications and hospitalisation. Regular hand hygiene can also help limit the spread of infection.
Flu and COVID-19 vaccines target different viruses. A flu shot does not protect against COVID-19, so eligible people may need separate vaccinations to reduce their risk of severe illness from both infections.
“Flu vaccination doesn't protect just yourself against the risk of having influenza but it also prevents transmission of infection to other vulnerable people around ourselves like little ones, elderly family members and people with medical conditions,” Dr. Bhawna Malik, Senior Consultant-Neonatologist and Pediatric Intensivist at Motherhood Hospitals, Greater Noida, told HealthandMe.
© $2026 Times Horizon Private Limited